BioCorRx Inc. (BICX) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BioCorRx Inc. (BICX) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. La acción obtiene una puntuación de 52/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 16 mar 2026BioCorRx Inc. (BICX) Resumen de Asistencia Médica y Tuberías
BioCorRx Inc. focuses on developing and distributing treatment programs for substance abuse and weight management, featuring its BioCorRx recovery program and UnCraveRx. Operating within the medical care facilities sector, the company leverages medication-assisted treatments and virtual support to address addiction and weight-related disorders in the United States.
Tesis de Inversión
BioCorRx Inc. presents a speculative investment opportunity within the substance abuse and weight management sectors. The company's proprietary naltrexone implant technology and the UnCraveRx program offer potential revenue streams, though profitability remains a challenge, as reflected in the negative P/E ratio of -1.41 and a substantial negative profit margin of -510.3%. The development of BICX101 and BICX104 could serve as future catalysts, pending regulatory approvals and successful clinical trials. The company's small market capitalization of $0.01 billion and limited number of employees (3) suggest a high-risk, high-reward scenario, contingent on successful product commercialization and market penetration. Investors should carefully consider the company's financial position and the competitive landscape before investing.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.01 billion, indicating a micro-cap company with high growth potential but also significant risk.
- P/E ratio of -1.41, reflecting current unprofitability but potential for future earnings growth.
- Gross margin of 53.9%, suggesting a solid foundation for profitability if operational costs are managed effectively.
- Negative profit margin of -510.3%, highlighting significant challenges in achieving profitability.
- Beta of 0.30, indicating lower volatility compared to the overall market.
Competidores y Pares
Fortalezas
- Proprietary naltrexone implant technology.
- Integrated counseling and medication-assisted treatment approach.
- Virtual support platform for weight management.
- Development pipeline of new naltrexone products (BICX101, BICX104).
Debilidades
- Small market capitalization and limited resources.
- Negative profitability and high operating expenses.
- Reliance on a small number of employees.
- OTC market listing, which may limit investor access.
Catalizadores
- Upcoming: Potential FDA approval of BICX101 (injectable naltrexone).
- Upcoming: Potential FDA approval of BICX104 (implantable naltrexone).
- Ongoing: Expansion of the BioCorRx recovery program to new healthcare providers.
- Ongoing: Growth in sales of the UnCraveRx weight loss management program.
- Ongoing: Strategic partnerships and acquisitions.
Riesgos
- Potential: Regulatory delays or rejection of BICX101 and BICX104.
- Potential: Competition from established pharmaceutical companies.
- Ongoing: Negative profitability and high operating expenses.
- Ongoing: Reliance on a small number of employees.
- Ongoing: Limited financial disclosure due to OTC listing.
Oportunidades de crecimiento
- Expansion of the BioCorRx Recovery Program: The market for medication-assisted treatment (MAT) is growing, driven by the opioid crisis and increasing acceptance of MAT as an effective treatment modality. BioCorRx can expand its reach by partnering with more healthcare providers and clinics across the United States. The addressable market for MAT is estimated to be billions of dollars, offering significant growth potential for BioCorRx.
- Development and Commercialization of BICX101 and BICX104: The successful development and approval of BICX101 (injectable naltrexone) and BICX104 (implantable naltrexone) represent significant growth opportunities. These products could provide more convenient and effective treatment options for opioid addiction and alcoholism. The market for long-acting injectable and implantable naltrexone products is substantial, with potential for significant revenue generation upon successful commercialization.
- Growth of the UnCraveRx Weight Loss Management Program: The weight loss market is a multi-billion dollar industry, driven by increasing obesity rates and demand for effective weight management solutions. BioCorRx can expand its UnCraveRx program by enhancing its virtual support platform, adding new features, and targeting specific customer segments. The program's medically assisted approach and virtual support offer a differentiated value proposition.
- Strategic Partnerships and Acquisitions: BioCorRx can pursue strategic partnerships and acquisitions to expand its product portfolio, geographic reach, and market share. Collaborating with other healthcare providers, technology companies, or pharmaceutical companies could accelerate growth and enhance the company's competitive position. Potential acquisition targets could include companies with complementary technologies or treatment programs.
- International Expansion: While currently focused on the United States, BioCorRx can explore opportunities for international expansion. The need for substance abuse and weight management solutions exists globally, and BioCorRx's programs could be adapted for use in other countries. International expansion would require careful planning and execution, but it could significantly expand the company's addressable market and revenue potential.
Oportunidades
- Expansion of the BioCorRx recovery program to more healthcare providers.
- Commercialization of BICX101 and BICX104.
- Growth of the UnCraveRx weight loss management program.
- Strategic partnerships and acquisitions.
Amenazas
- Competition from established pharmaceutical companies and treatment centers.
- Regulatory hurdles and potential delays in product approvals.
- Changes in healthcare policies and reimbursement rates.
- Potential for product liability claims.
Ventajas competitivas
- Proprietary naltrexone implant technology.
- Integrated counseling program with medication-assisted treatment.
- Virtual support platform for weight management.
- Development of new injectable and implantable naltrexone products.
Acerca de BICX
BioCorRx Inc., formerly known as Fresh Start Private Management, Inc. until its name change in January 2014, is dedicated to developing and providing treatment programs for substance abuse and related disorders in the United States. The company's core offering includes the BioCorRx recovery program, a non-addictive, medication-assisted treatment that combines a counseling program with its proprietary naltrexone implant. This program is distributed and licensed to healthcare providers, independent licensed clinics, and licensed healthcare professionals. In addition to substance abuse treatment, BioCorRx also offers the UnCraveRx weight loss management program. This medically assisted program aims to reduce food cravings through medication, coupled with on-demand virtual lifestyle support, fitness resources, and nutritional guidance. This dual approach addresses both addiction and weight management, reflecting a comprehensive approach to health and wellness. BioCorRx is also actively developing new products, including BICX101, an injectable naltrexone product, and BICX104, an implantable naltrexone implant specifically designed for the treatment of opioid addiction and alcoholism. These pipeline products indicate the company's commitment to expanding its treatment options and addressing critical needs in the addiction treatment landscape. Headquartered in Anaheim, California, BioCorRx operates primarily within the United States, focusing on providing innovative solutions for substance abuse and weight management.
Qué hacen
- Develops treatment programs for substance abuse and related disorders.
- Provides medication-assisted treatment programs.
- Distributes and licenses the BioCorRx recovery program, a non-addictive treatment.
- Offers a counseling program coupled with a proprietary naltrexone implant.
- Distributes the UnCraveRx weight loss management program.
- Provides medically assisted weight management to reduce food cravings.
- Offers on-demand virtual lifestyle support, fitness, and nutrition.
- Develops BICX101, an injectable naltrexone product, and BICX104, an implantable naltrexone implant.
Modelo de Negocio
- Licensing and distribution of the BioCorRx recovery program to healthcare providers and clinics.
- Direct sales of the UnCraveRx weight loss management program to individuals.
- Potential future revenue from sales of BICX101 and BICX104 upon regulatory approval.
- Partnerships with healthcare professionals for program implementation.
Contexto de la Industria
BioCorRx Inc. operates within the medical care facilities industry, addressing the growing needs for substance abuse and weight management solutions. The market for addiction treatment is expanding, driven by increasing awareness and the opioid crisis. The weight management market is also substantial, fueled by rising obesity rates and demand for effective solutions. BioCorRx competes with companies like BVAXF, FAMDF, GBCS, HLYK, and IONKF, which offer various treatment options and programs. The company's success depends on its ability to differentiate its products, navigate regulatory hurdles, and effectively market its programs to healthcare providers and individuals.
Clientes Clave
- Healthcare providers and independent licensed clinics.
- Licensed healthcare professionals.
- Individuals seeking treatment for substance abuse.
- Individuals seeking medically assisted weight management solutions.
Finanzas
Gráfico e información
Precio de la acción de BioCorRx Inc. (BICX): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Lows On Wednesday
· 2 oct 2019
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para BICX.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para BICX.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de BICX en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Lourdes Felix
Unknown
Information about Lourdes Felix's background is not available in the provided context. Without additional data, it is impossible to provide details about her career history, education, or previous roles. Her professional experience and qualifications remain unknown based on the current information.
Historial: Due to the limited information available, it is not possible to assess Lourdes Felix's track record or key achievements as CEO. Her strategic decisions and company milestones under her leadership cannot be evaluated without further data on her tenure and performance.
Información del mercado OTC de BICX
The OTC Other tier represents the lowest tier of the OTC market, indicating that BioCorRx Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to NYSE or NASDAQ-listed companies. These companies often do not adhere to standardized accounting practices, increasing the potential for fraud or misrepresentation.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and transparency.
- Higher risk of fraud or misrepresentation.
- Low liquidity and potential for price volatility.
- Limited regulatory oversight and investor protection.
- Potential for delisting or trading suspension.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Check for any red flags or warning signs.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC investing.
- Existence of a physical headquarters in Anaheim, California.
- Development of proprietary naltrexone implant technology.
- Distribution of the BioCorRx recovery program.
- Offering of the UnCraveRx weight loss management program.
- Development pipeline of new naltrexone products (BICX101, BICX104).
BICX Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar BICX?
BioCorRx Inc. (BICX) actualmente tiene una puntuación IA de 52/100, indicando puntuación moderada. Fortaleza clave: Proprietary naltrexone implant technology.. Riesgo principal a monitorear: Potential: Regulatory delays or rejection of BICX101 and BICX104.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de BICX?
BICX actualmente puntúa 52/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de BICX?
Los precios de BICX se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre BICX?
La cobertura de analistas para BICX incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en BICX?
Las categorías de riesgo para BICX incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Regulatory delays or rejection of BICX101 and BICX104.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de BICX?
La relación P/E para BICX compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está BICX sobrevalorada o infravalorada?
Determinar si BioCorRx Inc. (BICX) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de BICX?
BioCorRx Inc. (BICX) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.
- Lack of analyst coverage limits the availability of expert opinions.